Elisa García Garre

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17

Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables

Alejandra Ivars Rubio, Juan Carlos Yufera, Pilar de la Morena et al. · Scientific Reports · 2019 · 32 citations · Full text

Medicine, Immunology, Oncology +15

Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis

Ginés Luengo‐Gil, Enrique González‐Billalabeitia, Asunción Cháves-Benito et al. · Breast Cancer Research and Treatment · 2015 · 24 citations

Medicine, Cancer Biology, Oncology +14

Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis

Elisa García Garre, Ginés Luengo‐Gil, Silvia Montoro García et al. · Breast Cancer Research and Treatment · 2018 · 16 citations

Medicine, Cancer Biology, Oncology +17